Publications by authors named "O K Tsun"
Article Synopsis
- The study assessed the agreement of HPV test results between self-collected samples and clinician-collected samples using two different HPV assays: Sentis (isothermal amplification) and Onclarity (PCR-based).
- Among 104 women, the concordance rates were high, with 89.8% between Self-Sentis and Clinician-Sentis, and 84.4% between Self-Sentis and Clinician-Onclarity.
- The findings showed that a significant number (65%) of participants found self-sampling to be acceptable, mainly due to reduced embarrassment and convenience.
This study aimed (i) to compare the performance of the BD Onclarity human papillomavirus (HPV) assay with the Cobas HPV test in identifying cervical intraepithelial neoplasia 2/3 or above (CIN2/3+) in an Asian screening population and (ii) to explore improving the cervical cancer detection specificity of Onclarity by machine learning. We tested 605 stratified random archived samples of cervical liquid-based cytology samples with both assays. All samples had biopsy diagnosis or repeated negative cytology follow-up.
View Article and Find Full Text PDFBackground: High-risk human papillomavirus (hrHPV) detection and genotyping by Cobas HPV test has become an important technical platform in cervical cancer screening. It may be used as a co-test with cervical cytology or as a standalone test. Aptima HPV assay (AHPV) is another hrHPV test detecting 13 genotypes through qPCR based amplification of viral E6/E7 transcripts.
View Article and Find Full Text PDFObjective: To evaluate the performance of an automated DNA-image-cytometry system as a tool to detect cervical carcinoma.
Methods: Of 384 liquid-based cervical cytology samples with available biopsy follow-up were analyzed by both the Imager System and a high-risk HPV test (Cobas).
Results: The sensitivity and specificity of Imager System for detecting biopsy proven high-grade squamous intraepithelial lesion (HSIL, cervical intraepithelial neoplasia [CIN]2-3) and carcinoma were 89.
Objectives: To compare the PathVysion fluorescence in-situ hybridisation assay with the INFORM HER2 Dual in-situ hybridisation assay on 104 invasive breast cancers with a broad spectrum of immunohistochemistry scores.
Methods: This case series involved consecutive patients diagnosed with invasive breast carcinoma with equivocal immunohistochemistry score and referred for further HER2 assessment from the departments of Surgery and/or Clinical Oncology of the two hospitals between January 2013 and February 2014. An additional 10 cases with negative HER2 immunohistochemistry and 11 cases with positive HER2 immunohistochemistry were further included.